Sun Pharmaceutical Industries Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 5 per equity share.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma's Board of Directors recommended a final dividend of Rs. 5 per equity share (face value Rs. 1 each) for FY 2025-26, pending shareholder approval at the 34th AGM. This is in addition to an interim dividend of Rs. 11 per share already declared on January 31, 2026, bringing the total dividend for the year to Rs. 16 per share. For the full year ended March 2026, standalone revenue from operations declined to Rs. 206,090.2 million from Rs. 225,984 million the previous year. Net profit after tax fell to Rs. 6,087 million from Rs. 26,234.2 million, impacted by exceptional items including impairment of SCD-044 drug development (Rs. 2,876.4 million) and new labour code implementation costs (Rs. 2,587 million). EPS for the year was Rs. 10.9 versus Rs. 17.6 in the prior year. The auditors issued an unmodified opinion on the financial results.
The company maintained dividend payouts despite a significant decline in profitability due to one-time charges. Shareholders can expect Rs. 16 total dividend per share for FY 2025-26 once approved.